- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT03681600
Observatory of the Quality of Surgical Procedures for Digestive Cancers (Obchir)
Observatory of the Quality of Surgical Procedures for Digestive Cancers: Pilot Project.
Surgery for digestive cancers is managed according to quality standards, validated by the scientific community. Despite the diffusion of these standards through the benchmarks of good practice, the results of the surgery remain disparate.
In many countries, this "inequality of opportunity" has justified the establishment of quality assurance systems to measure the results of surgery for one or more localizations of digestive cancer.
These surgical audit experiments have shown a positive, rapid and cost-effective impact on complication rates, recurrence rates and overall survival even in the absence of interventional measures. The data collected also helped to improve the management of subgroups of patients usually excluded from clinical trials.
In Morocco, the National Cancer Prevention and Control Plan provides for the establishment of a quality assurance system with the introduction of a system for monitoring and evaluating the care of patients. This pilot project is part of this framework, for the group of patients who are candidates for surgery for digestive cancers.
Panoramica dello studio
Stato
Tipo di studio
Iscrizione (Effettivo)
Contatti e Sedi
Luoghi di studio
-
-
-
Oujda, Marocco
- Regional center of oncology, surgical department
-
Rabat, Marocco, 10100
- Ibn Sina Hospital, Surgical department A
-
Rabat, Marocco, 10100
- Ibn Sina Hospital, Surgical department C
-
-
Please Enter The State Or Province
-
Rabat, Please Enter The State Or Province, Marocco, 10100
- National Institut of Oncology, Surgical oncology department
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
- patients operated for a digestive cancer, proven or suspected, in a curative or palliative intent In elective situation: inclusion from surgery programming In emergent situation: inclusion no later than 72 hours after surgery
- Cancer proven or suspected in the following digestive tract: colon, appendix, anus, rectum, esophagus, stomach, eso-gastric junction, bile ducts, ampulla of Vater , pancreas, duodenum, small intestine and liver.
- Patient willing and able to agree to participate in the study
Exclusion Criteria:
Patient whose surgical intervention is indicated for:
- a condition that is not a digestive tract cancer, including whether retrospectively surgical exploration and / or histological examination reveals digestive localization cancer
- proven or suspected cancer of non-digestive location
- a proven or suspected cancer of peritoneal localization
- Patient whose surgical intervention is indicated for a progressive disease or a local recurrence proven or suspected of a digestive localization cancer having already been the resected (with the exception of situations of iterative liver resection for liver metastasis hepatic and recovery of the tumor bed after the discovery of vesicular cancer on cholecystectomy specimen)
- Patients whose intervention is for diagnostic purposes without any curative or palliative intention
- Patients whose surgery is a liver transplant
- Patients whose surgical intervention is local destruction (radiofrequency, microwaves) exclusively by percutaneous approach (without laparotomy or laparoscopy)
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
90-day Mortality rate
Lasso di tempo: 90 days from surgery
|
Death within 90 days of surgical procedure
|
90 days from surgery
|
|
90-day Complication rate
Lasso di tempo: 90 days from surgery
|
Defined with by Clavien-Dindo grade I to IV within90 days of surgical procedure
|
90 days from surgery
|
|
3-year Overall survival
Lasso di tempo: from the date of operation to date of death from any cause, whichever came first, assessed up to 3 year
|
Overall survival is defined as time from initiation to death of any cause within 3years of surgical procedure
|
from the date of operation to date of death from any cause, whichever came first, assessed up to 3 year
|
|
3-year disease free survival
Lasso di tempo: from operation until recurrence of tumor or death from any cause, whichever came first, assessed up to 3 years
|
Disease free survival is defined as time from initiation to death of any cause within 3years of surgical procedure
|
from operation until recurrence of tumor or death from any cause, whichever came first, assessed up to 3 years
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Treatment decisions made within multidisciplinary team meeting / tumour board
Lasso di tempo: Prior to surgery
|
For every localization
|
Prior to surgery
|
|
Availability/performance of CT chest, abdomen and pelvis scan performed for pre-operative staging
Lasso di tempo: Prior to surgery
|
For every localization
|
Prior to surgery
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Direttore dello studio: Amine Benkabbou, Pr, Moroccan Society of Surgery
- Investigatore principale: Raouf Mohsine, Pr, National institut of oncology
- Investigatore principale: Abdelmalek Hrora, Pr, Moroccan Society of Surgery
Pubblicazioni e link utili
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- MoroccanSS
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .